Effect of fragmented Lactobacillus amylovorus CP1563 on lipid metabolism in overweight and mildly obese individuals: a randomized controlled trial
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Previously, we showed that fragmented Lactobacillus amylovorus CP1563 (CP1563) functions as a dual agonist of peroxisome proliferator-activated receptor α and γ in vitro and in vivo. OBJECTIVE: Here, we examined the safety and effect of CP1563 ingestion on body fat in obese class I participants in a double-blinded, placebo-controlled, randomized clinical trial (RCT). DESIGN: In the RCT, 200 participants with a body mass index (BMI) of 25-30 kg/m(2) consumed test beverages with or without 200 mg of CP1563 daily for 12 weeks. In total, 197 subjects completed the study without any adverse effects. RESULTS: Body fat percentage, whole body fat, and visceral fat were significantly decreased in the test group compared with the placebo group (p<0.001, p<0.001, and p<0.001, respectively). Triglycerides, total cholesterol, LDL-cholesterol, and diastolic blood pressure showed significant reductions in the test group compared with the placebo group (p<0.001, p<0.001, p<0.001, and p<0.001, respectively). Additionally, significant differences in the changes in blood glucose, insulin, homeostasis model assessment-insulin resistance (HOMA-IR), and uric acid were observed between the two groups (p<0.001, p=0.004, p<0.001, and p<0.001, respectively). Improvements in anthropometric measurements and markers were observed in obese class I subjects in the test group. CONCLUSIONS: Daily consumption of beverages containing fragmented CP1563 for 12 weeks by obese class I subjects improved anthropometric measurements and markers related to lipid and glucose metabolism without any adverse effects. These results suggest that the consumption of foods containing fragmented CP1563 reduces body fat and prevents metabolic syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms linking obesity with cardiovascular disease
Van Gaal, L. F., Mertens, I. L., & De Block, C. E. (2006) · Nature · doi:10.1038/nature05487 · Cited by 2,814
Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes.
Guilherme, A., Virbasius, J. V., Puri, V., & Czech, M. P. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2391 · Cited by 2,292
Dietary factors and low-grade inflammation in relation to overweight and obesity
Calder, P. C., Ahluwalia, N., Brouns, F., Buetler, T., Clement, K., Cunningham, K., Esposito, K., Jönsson, L. S., Kolb, H., Lansink, M., et al. (2011) · British Journal of Nutrition · doi:10.1017/s0007114511005460 · Cited by 1,098
Gut microbiota and metabolic syndrome
Festi, D., Schiumerini, R., Eusebi, L. H., Marasco, G., Taddia, M., & Colecchia, A. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i43.16079 · Cited by 534 · cited 1×
“In lipid metabolism, a close relationship between the composition of gut microbiota and obesity might exist, although conflicting research findings have been reported (26).”
BackgroundThe influence of the human microbiome and probiotics on cardiovascular health
Ettinger, G., MacDonald, K., Reid, G., & Burton, J. P. (2014) · Gut Microbes · doi:10.4161/19490976.2014.983775 · Cited by 180
Leslie, M. A., Cohen, D. J. A., Liddle, D. M., Robinson, L. E., & Ma, D. W. L. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0049-7 · Cited by 143 · cited 1×
“For example, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are PPARa agonists, and they are representative of foods that affect lipid metabolism, as supported by abundant evidence from clinical studies (25).”
Background
Cited by
Salminen, S., Collado, M. C., Endo, A., Hill, C., Lebeer, S., Quigley, E. M. M., Sanders, M. E., Shamir, R., Swann, J. R., Szajewska, H., et al. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00440-6 · Cited by 2,488
Swanson, K. S., Gibson, G. R., Hutkins, R., Reimer, R. A., Reid, G., Verbeke, K., Scott, K. P., Holscher, H. D., Azad, M. B., Delzenne, N. M., et al. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0344-2 · Cited by 2,196
Borgeraas, H., Johnson, L. K., Skattebu, J., Hertel, J. K., & Hjelmesæth, J. (2018) · Obesity Reviews · doi:10.1111/obr.12626 · Cited by 278
Kim, D., Jeong, D., Kang, I., Kim, H., Song, K., & Seo, K. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700252 · Cited by 122
Porchia, L. M., Vazquez-Marroquin, G., Ochoa-Précoma, R., Pérez-Fuentes, R., & Gonzalez-Mejia, M. E. (2022) · European Journal of Clinical Nutrition · doi:10.1038/s41430-022-01135-0 · Cited by 10
Metadata
- Authors
- Nakamura, F., Ishida, Y., Aihara, K., Sawada, D., Ashida, N., Sugawara, T., Aoki, Y., Takehara, I., Takano, K., & Fujiwara, S.
- Venue
- Microbial Ecology in Health & Disease
- Publisher
- Co-Action Publishing
- Published
- 2016-05-23
- Volume
- 27
- Issue
- 0
- Pages
- 30312-30312
- ISSN
- 0891-060X (ISSN-L)
- 1651-2235
- OpenAlex
- W2406729335
- Cited by
- 47
- References
- 6
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of fragmented Lactobacillus amylovorus CP1563 on lipid metabolism in overweight and mildly obese individuals: a randomized controlled trial. https://app.cochat.ai/papers/10.3402/mehd.v27.30312
- The paper
- Nakamura, F., Ishida, Y., Aihara, K., Sawada, D., Ashida, N., Sugawara, T., Aoki, Y., Takehara, I., Takano, K., & Fujiwara, S. (2016). Effect of fragmented Lactobacillus amylovorus CP1563 on lipid metabolism in overweight and mildly obese individuals: a randomized controlled trial. Microbial Ecology in Health & Disease. https://doi.org/10.3402/mehd.v27.30312
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.